Trials / Active Not Recruiting
Active Not RecruitingNCT05658562
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
A Phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
\[Phase I part\] To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, the dose to be used in the Phase II part will be confirmed. \[Phase II part\] To evaluate the efficacy of MT-2111 monotherapy in patients with relapsed/refractory DLBCL. In addition, the safety and pharmacokinetics will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-2111 | i.v. infusion |
Timeline
- Start date
- 2023-01-30
- Primary completion
- 2028-08-01
- Completion
- 2028-08-01
- First posted
- 2022-12-20
- Last updated
- 2026-02-13
Locations
23 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05658562. Inclusion in this directory is not an endorsement.